Investment Advice

Showing 2908 articles
Business

Atlassian's Steep Slide: Is the Collaboration Giant Now a Value Play?

After a punishing 61% decline in its share price over the past year, Atlassian finds itself at a critical juncture. With the stock trading near $118, investors are grappling with whether this represents a profound disconnect from long-term potential or a justified reassessment of growth prospects in a shifting market.

Business

Gilead Sciences Oncology Update After Positive Trodelvy Keytruda Trial Results

Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...

Business

McEwen Mining's Valuation Puzzle: Mixed Signals Amid Precious Metals Volatility

McEwen Mining (NYSE: MUX) presents a complex picture for investors, with recent share price movements showing short-term declines against a backdrop of longer-term gains. As the market digests its latest financial results—$166.5 million in revenue alongside an $11.9 million net loss—questions arise about how to value its exposure to gold, silver, and copper. This analysis delves into the valuation metrics and market sentiment surrounding the miner.